News

Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Lonza announced their agreement in support of ARU-1801, Aruvant’s one-time investigational gene therapy for sickle cell disease (SCD). Aruvant has chosen Lonza to help develop...

ViGeneron GmbH, a gene therapy company, announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited, for delivering a novel therapeutic protein to address an undisclosed target in a highly prevalent...

Novartis and GSK announced the launch of a collaboration to support high-quality scientific research investigating the link between genetic diversity across different regions in Africa and its potential impact on response to drug therapeutics. The Project Africa Genomic Research Approach...

“NextPharma is an established and well-respected company, with extensive experience in oral and topical finished dosage forms. As such, it is the ideal buyer given the technologies available at the Ploermel and Edinburgh sites. We are confident that the...

Intravacc, a world leader in translational research and development of vaccines, announced that a candidate polyvalent inactivated coxsackievirus B (CVB) vaccine it developed and manufactured for Provention Bio in less than 36 months, has entered into a first in...

Brazil has granted approval to AstraZeneca and Chinese firm Sinovac Biotech’c Covid-19 vaccines for emergency use, allowing the country to begin inoculation as cases surge. Brazilian health regulator Anvisa approved the vaccines citing a rise in cases, as well as...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. FDA approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients...